UBXN11 and neoplasm: Combining SoC with αPD1 + αGITR therapy, however, significantly increased the lifespan of tumor-bearing mice and increased the fraction of the long-term survivors compared to αPD1 + αGITR in CT2A-bearing mice (Fig. 3r).